Is HURA or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media refer more to HURA or ARTV?

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.16 beat Artiva Biotherapeutics' score of 0.95 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CAPR or HURA more profitable?

Capricor Therapeutics' return on equity of -56.60% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% TuHURA Biosciences N/A -156.47% -106.98%

Does the media prefer CAPR or HURA?

In the previous week, Capricor Therapeutics had 40 more articles in the media than TuHURA Biosciences. MarketBeat recorded 44 mentions for Capricor Therapeutics and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.16 beat Capricor Therapeutics' score of 0.09 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HURA or ENTX more profitable?

Entera Bio's return on equity of -147.19% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Entera Bio N/A -147.19% -103.22%

Does the media refer more to PRTA or HURA?

In the previous week, TuHURA Biosciences had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for TuHURA Biosciences and 2 mentions for Prothena. TuHURA Biosciences' average media sentiment score of 1.16 beat Prothena's score of 0.93 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, KYTX or HURA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$2.94 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A

Is KYTX or HURA more profitable?

Kyverna Therapeutics' return on equity of -81.92% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.92% -63.74% TuHURA Biosciences N/A -156.47% -106.98%

Does the media favor KYTX or HURA?

In the previous week, TuHURA Biosciences had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for TuHURA Biosciences and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat TuHURA Biosciences' score of 1.16 indicating that Kyverna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TuHURA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TuHURA Biosciences (HURA) Competitors

$2.05 +0.02 (+0.99%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.01 (+0.24%)

As of 09/11/2026 07:30 PM Eastern

Compare

HURA vs. ARTV, CAPR, ENTX, PRTA, and KYTX

Should you buy TuHURA Biosciences stock or one of its competitors? TuHURA Biosciences's main competitors and comparable companies include Artiva Biotherapeutics (ARTV), Capricor Therapeutics (CAPR), Entera Bio (ENTX), Prothena (PRTA), and Kyverna Therapeutics (KYTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

TuHURA Biosciences has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

Artiva Biotherapeutics' return on equity of -53.86% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

TuHURA Biosciences presently has a consensus price target of $9.00, indicating a potential upside of 339.02%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 281.60%. Given TuHURA Biosciences' higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

TuHURA Biosciences has higher earnings, but lower revenue than Artiva Biotherapeutics. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Artiva Biotherapeutics	$250K	1,998.62	-$83.86M	-$3.30	N/A

0.6% of TuHURA Biosciences shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 7 mentions for Artiva Biotherapeutics and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.16 beat Artiva Biotherapeutics' score of 0.95 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TuHURA Biosciences and Artiva Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Capricor Therapeutics currently has a consensus target price of $29.15, suggesting a potential upside of 248.27%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 339.02%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Capricor Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	7 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TuHURA Biosciences has lower revenue, but higher earnings than Capricor Therapeutics. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	21.85	-$105.04M	-$2.45	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Capricor Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 40 more articles in the media than TuHURA Biosciences. MarketBeat recorded 44 mentions for Capricor Therapeutics and 4 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.16 beat Capricor Therapeutics' score of 0.09 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics' return on equity of -56.60% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
TuHURA Biosciences	N/A	-156.47%	-106.98%

Summary

Capricor Therapeutics beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Entera Bio?

TuHURA Biosciences (NASDAQ:HURA) and Entera Bio (NASDAQ:ENTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 10.6% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, TuHURA Biosciences had 3 more articles in the media than Entera Bio. MarketBeat recorded 4 mentions for TuHURA Biosciences and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat TuHURA Biosciences' score of 1.16 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
TuHURA Biosciences	Positive
Entera Bio	Very Positive

TuHURA Biosciences has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market. Comparatively, Entera Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Entera Bio's return on equity of -147.19% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Entera Bio	N/A	-147.19%	-103.22%

TuHURA Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 339.02%. Entera Bio has a consensus target price of $9.00, indicating a potential upside of 216.90%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Entera Bio has higher revenue and earnings than TuHURA Biosciences. Entera Bio is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Entera Bio	$40K	12,341.93	-$11.44M	-$0.35	N/A

Summary

Entera Bio beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Prothena?

Prothena (NASDAQ:PRTA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Prothena currently has a consensus target price of $24.57, suggesting a potential upside of 175.16%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 339.02%. Given TuHURA Biosciences' higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, TuHURA Biosciences had 2 more articles in the media than Prothena. MarketBeat recorded 4 mentions for TuHURA Biosciences and 2 mentions for Prothena. TuHURA Biosciences' average media sentiment score of 1.16 beat Prothena's score of 0.93 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.45% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-80.68%	-16.45%	-14.51%
TuHURA Biosciences	N/A	-156.47%	-106.98%

TuHURA Biosciences has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	48.29	-$244.09M	-$0.84	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Prothena has a beta of -0.33, suggesting that its stock price is 133% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

97.1% of Prothena shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TuHURA Biosciences beats Prothena on 8 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Kyverna Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 313.22%. TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 339.02%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kyverna Therapeutics' return on equity of -81.92% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.92%	-63.74%
TuHURA Biosciences	N/A	-156.47%	-106.98%

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 17.6% of Kyverna Therapeutics shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, TuHURA Biosciences had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 4 mentions for TuHURA Biosciences and 3 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.61 beat TuHURA Biosciences' score of 1.16 indicating that Kyverna Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TuHURA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$2.94	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Kyverna Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market.

Summary

Kyverna Therapeutics and TuHURA Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$130.64M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-3.80	8.41	214.39	20.85
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	6.03	15.12	10.33	6.21
Net Income	-$30.05M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-4.21%	-4.34%	-3.32%	-2.35%
1 Month Performance	-10.87%	0.54%	-0.53%	-3.23%
1 Year Performance	-18.00%	40.74%	23.51%	8.79%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	2.0279 of 5 stars	$2.05 +1.0%	$9.00 +339.0%	-18.0%	$130.64M	N/A	N/A	N/A	Positive News
ARTV Artiva Biotherapeutics	3.3832 of 5 stars	$10.97 -2.0%	$39.00 +255.6%	+300.8%	$536.42M	$250K	N/A	81	Insider Trade
CAPR Capricor Therapeutics	2.9333 of 5 stars	$8.95 -4.8%	$29.15 +225.7%	+31.6%	$521.51M	N/A	N/A	101	Trending News Gap Up
ENTX Entera Bio	2.7447 of 5 stars	$2.94 -2.0%	$9.00 +206.1%	+57.8%	$510.89M	$40K	N/A	20	Positive News Gap Up
PRTA Prothena	3.1151 of 5 stars	$9.59 -2.3%	$24.57 +156.1%	+8.8%	$502.09M	$9.68M	N/A	130	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. ARTV, CAPR, ENTX, PRTA, and KYTX

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

Summary

How does TuHURA Biosciences compare to Capricor Therapeutics?

Summary

How does TuHURA Biosciences compare to Entera Bio?

Summary

How does TuHURA Biosciences compare to Prothena?

Summary

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. ARTV, CAPR, ENTX, PRTA, and KYTX

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

Which has more risk and volatility, HURA or ARTV?

Is HURA or ARTV more profitable?

Do analysts rate HURA or ARTV?

Which has preferable valuation and earnings, HURA or ARTV?

Do institutionals & insiders believe in HURA or ARTV?

Does the media refer more to HURA or ARTV?

Summary

How does TuHURA Biosciences compare to Capricor Therapeutics?

Do analysts prefer CAPR or HURA?

Do institutionals and insiders hold more shares of CAPR or HURA?

Which has better valuation & earnings, CAPR or HURA?

Which has more risk and volatility, CAPR or HURA?

Does the media prefer CAPR or HURA?

Is CAPR or HURA more profitable?

Summary

How does TuHURA Biosciences compare to Entera Bio?

Do insiders and institutionals have more ownership in HURA or ENTX?

Does the media prefer HURA or ENTX?

Which has more volatility and risk, HURA or ENTX?

Is HURA or ENTX more profitable?

Do analysts prefer HURA or ENTX?

Which has better valuation & earnings, HURA or ENTX?

Summary

How does TuHURA Biosciences compare to Prothena?

Do analysts rate PRTA or HURA?

Does the media refer more to PRTA or HURA?

Is PRTA or HURA more profitable?

Which has better earnings & valuation, PRTA or HURA?

Which has more risk and volatility, PRTA or HURA?

Do institutionals and insiders have more ownership in PRTA or HURA?

Summary

How does TuHURA Biosciences compare to Kyverna Therapeutics?

Do analysts rate KYTX or HURA?

Is KYTX or HURA more profitable?

Do insiders & institutionals have more ownership in KYTX or HURA?

Does the media favor KYTX or HURA?

Which has higher earnings and valuation, KYTX or HURA?

Which has more volatility & risk, KYTX or HURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools